DAM
HRTX icon

Deltec Asset Management’s Heron Therapeutics HRTX Stock Holding History

Deltec Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-117,000
Closed -$2.12M – 189
2017
Q4 		$2.12M Buy
+117,000
New +$1.91M 0.43% 62

Other funds holding HRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deltec Asset Management's HRTX Position: Q1 2018 in Review

Deltec Asset Management sold out of Heron Therapeutics (HRTX) in Q1 2018, closing a stake of 117,000 shares — an estimated $2.12M sold.

Deltec Asset Management first reported a position in HRTX in Q4 2017 and held it in 1 quarter. The position peaked at $2.12M in Q4 2017. 152 funds tracked by Wall St. Rank hold HRTX as of Q1 2018.

  • Deltec Asset Management reported no remaining Heron Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Deltec Asset Management sold 117,000 Heron Therapeutics shares in Q1 2018, an estimated $2.12M.
  • Deltec Asset Management first reported a position in Heron Therapeutics in Q4 2017 and held it in 1 quarter.
  • Deltec Asset Management's Heron Therapeutics position peaked at $2.12M in Q4 2017.
  • 152 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2018.

Based on Deltec Asset Management's 13F filing for Q1 2018, filed 11 May 2018.